- On October 1, 2025, Kairos Pharma, Ltd. (Kairos) entered into a novation agreement with Cedars-Sinai Medical Center to transfer the exclusive license of two patents from its wholly-owned subsidiary, Enviro Therapeutics, Inc., to Kairos, effective **April 17, 2025**.  **[1962011_0001493152-25-017208_form8-k.htm:0]** **[1962011_0001493152-25-017208_ex10-1.htm:0]** 
- Kairos also assumed rights and obligations for **TRC105 and CD105 technologies** from Tracon Pharmaceuticals, Inc., previously held by Enviro, through a novation agreement effective **September 24, 2025**.  **[1962011_0001493152-25-017208_ex10-2.htm:0]** **[1962011_0001493152-25-017208_form8-k.htm:1]** 
- Kairos announced on October 7, 2025, that it will present **"Preliminary safety and clinical activity from a Phase 2 study of apalutamide and carotuximab in advanced, castration-resistant prostate cancer"** at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, from **October 17–21, 2025**.  **[1962011_0001493152-25-017208_ex99-1.htm:0]** **[1962011_0001493152-25-017208_form8-k.htm:2]** 
- The presentation will highlight interim analysis results from a Phase 2 trial evaluating **ENV105 (carotuximab)**, a first-in-class CD105 antagonist, in **100 men** with metastatic castration-resistant prostate cancer (mCRPC), demonstrating **encouraging safety and early efficacy findings**.  **[1962011_0001493152-25-017208_ex99-1.htm:0]**

Kairos Pharma to Present Positive Phase 2 Prostate Cancer Data at ESMO 2025 and Assumes Key Licenses

- **Kairos Pharma, Ltd. (KAPA)** announced **positive interim efficacy data** from its ongoing Phase 2 clinical trial of **ENV105 (carotuximab)** for metastatic castration-resistant prostate cancer (mCRPC) on **September 18, 2025**.  **[1962011_0001493152-25-013975_ex99-1.htm:0]** **[1962011_0001493152-25-013975_form8-k.htm:1]** 
- The interim analysis of 8 patients demonstrated a **median progression-free survival of more than 13 months** for ENV105 in combination with apalutamide, significantly exceeding the 3.7 months median efficacy of standard of care hormone therapy.  **[1962011_0001493152-25-013975_ex99-1.htm:0]** 
- **Seven of nine patients** in the interim analysis showed a decrease in their prostate-specific antigen (PSA) from baseline.  **[1962011_0001493152-25-013975_ex99-1.htm:0]** 
- An earlier interim safety analysis in July 2025 indicated that ENV105 was **well tolerated**, with no dose-limiting toxicities or unexpected adverse events reported.  **[1962011_0001493152-25-013975_ex99-1.htm:0]**

Kairos Pharma (KAPA)